Georges Joseph F, Liu Xiaowei, Eschbacher Jennifer, Nichols Joshua, Mooney Michael A, Joy Anna, Spetzler Robert F, Feuerstein Burt G, Preul Mark C, Anderson Trent, Yan Hao, Nakaji Peter
Division of Neuroscience, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona; Division of Neurological Surgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona.
The Biodesign Institute, Arizona State University, Tempe, Arizona.
PLoS One. 2015 Apr 15;10(4):e0123607. doi: 10.1371/journal.pone.0123607. eCollection 2015.
Improved tools for providing specific intraoperative diagnoses could improve patient care. In neurosurgery, intraoperatively differentiating non-operative lesions such as CNS B-cell lymphoma from operative lesions can be challenging, often necessitating immunohistochemical (IHC) procedures which require up to 24-48 hours. Here, we evaluate the feasibility of generating rapid ex vivo specific labeling using a novel lymphoma-specific fluorescent switchable aptamer. Our B-cell lymphoma-specific switchable aptamer produced only low-level fluorescence in its unbound conformation and generated an 8-fold increase in fluorescence once bound to its target on CD20-positive lymphoma cells. The aptamer demonstrated strong binding to B-cell lymphoma cells within 15 minutes of incubation as observed by flow cytometry. We applied the switchable aptamer to ex vivo xenograft tissue harboring B-cell lymphoma and astrocytoma, and within one hour specific visual identification of lymphoma was routinely possible. In this proof-of-concept study in human cell culture and orthotopic xenografts, we conclude that a fluorescent switchable aptamer can provide rapid and specific labeling of B-cell lymphoma, and that developing aptamer-based labeling approaches could simplify tissue staining and drastically reduce time to histopathological diagnoses compared with IHC-based methods. We propose that switchable aptamers could enhance expeditious, accurate intraoperative decision-making.
用于提供特定术中诊断的改进工具可以改善患者护理。在神经外科手术中,术中区分非手术性病变(如中枢神经系统B细胞淋巴瘤)和手术性病变可能具有挑战性,通常需要免疫组织化学(IHC)程序,这需要长达24至48小时。在此,我们评估了使用新型淋巴瘤特异性荧光可切换适体产生快速离体特异性标记的可行性。我们的B细胞淋巴瘤特异性可切换适体在其未结合构象中仅产生低水平荧光,一旦与CD20阳性淋巴瘤细胞上的靶标结合,荧光就会增加8倍。通过流式细胞术观察,适体在孵育15分钟内显示出与B细胞淋巴瘤细胞的强结合。我们将可切换适体应用于携带B细胞淋巴瘤和星形细胞瘤的离体异种移植组织,并且在一小时内常规地能够对淋巴瘤进行特异性视觉识别。在这项针对人类细胞培养和原位异种移植的概念验证研究中,我们得出结论,荧光可切换适体可以对B细胞淋巴瘤进行快速且特异性的标记,并且与基于IHC方法相比,开发基于适体的标记方法可以简化组织染色并大幅减少组织病理学诊断的时间。我们提出可切换适体可以增强快速、准确的术中决策。